Evidence map›Paper›PMID 36819781›Full record

ArticleOxidative medicine and cellular longevity2023

Traxoprodil Produces Antidepressant-Like Behaviors in Chronic Unpredictable Mild Stress Mice through BDNF/ERK/CREB and AKT/FOXO/Bim Signaling Pathway.

Yahui Wang, Zehuai Liang, Wenyue Song, Yu Qin, Noah Todd, Mingqi Gao

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Antioxidants (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Yahui WangSchool of Pharmacy, China Medical University, Shenyang 110122, China.ORCID https://orcid.org/0000-0001-6403-7222
Zehuai LiangSchool of Pharmacy, China Medical University, Shenyang 110122, China.ORCID https://orcid.org/0000-0002-4565-9197
Wenyue SongSchool of Pharmacy, China Medical University, Shenyang 110122, China.ORCID https://orcid.org/0000-0002-0838-6687
Yu QinSchool of Pharmacy, China Medical University, Shenyang 110122, China.ORCID https://orcid.org/0000-0002-3531-6406
Noah ToddSchool of Medicine, Indiana University, Fort Wayne 46805, USA.ORCID https://orcid.org/0000-0001-8509-1025
Mingqi GaoSchool of Pharmacy, China Medical University, Shenyang 110122, China.ORCID https://orcid.org/0000-0002-5059-5992
China Medical University · CNIndiana University Fort Wayne · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traxoprodil is a selective N-methyl-d-aspartate receptor subunit 2B (NR2B) receptor inhibitor with rapid and long-lasting antidepressant effects. However, the appropriate dosage, duration of administration, and underlying mechanism of traxoprodil's antidepressant effects remain unclear. The purpose of this study is to compare the antidepressant effects of traxoprodil in different doses and different durations of administration and to explore whether traxoprodil exerts antidepressant effects via the brain-derived neurotrophic factor/extracellular signal-regulated kinase/cAMP-response element binding protein (BDNF/ERK/CREB) and protein kinase B/Forkhead box O/building information modelling (AKT/FOXO/Bim) signaling pathway. Mice were randomly divided into control group, chronic unpredictable mild stress (CUMS) + vehicle group, CUMS + traxoprodil (10 mg/kg, 20 mg/kg, and 40 mg/kg) groups, and CUMS + fluoxetine (5 mg/kg) group, followed by a forced swimming test, tail suspension test, and sucrose preference test. Western blotting and immunohistochemistry were used to measure the protein expression of BDNF, p-ERK1/2, p-CREB, NR2B, AKT, FOXO1, FOXO3a, and Bim. Compared with the control group, CUMS treatment increased immobility time; decreased sucrose preference; reduced expression of BDNF, p-ERK1/2, and p-CREB; and increased expression of AKT, FOXO, and Bim in the hippocampus. These alterations were ameliorated by administration of 20 mg/kg or 40 mg/kg of traxoprodil after 7 or 14 days of administration and with 10 mg/kg of traxoprodil or 5 mg/kg of fluoxetine after 21 days of administration. At the 7-day and 14-day timepoints, traxoprodil displayed dose-dependent antidepressant effects, with 20 and 40 mg/kg doses of traxoprodil producing rapid and strong antidepressant effects. However, at 21 days of administration, 10 and 20 mg/kg doses of traxoprodil exerted more pronounced antidepressant effects. The mechanism of traxoprodil's antidepressant effects may be closely related to the BDNF/ERK/CREB and AKT/FOXO/Bim signaling pathway.

Indexed as

DepressionFluoxetineAnimalsAntidepressive AgentsBrain-Derived Neurotrophic FactorDisease Models, AnimalHippocampusMicePiperidinesProto-Oncogene Proteins c-aktSignal TransductionSucroseAntidepressive AgentsBrain-Derived Neurotrophic FactorFluoxetinePiperidinesProto-Oncogene Proteins c-aktSucrosetraxoprodil mesylate

Identifiers

PMID36819781
PMCPMC9937761
OpenAlexW4319869203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.